Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Minerva Neurosciences Inc (NERV) Shares Skyrocket Following Successful Schizophrenia Drug Trial

Shares of Minerva Neurosciences Inc (NASDAQ:NERV) have surged by more than 235% today after the company announced positive results from the Phase IIb trial of its antidepressant drug candidate MIN-101. Results from the study proved the superiority of MIN-101 compared to a placebo in its primary endpoint of improving negative symptoms, which is judged using the pentagonal structure model (PSM) of the Positive and Negative Syndrome Scale (PANSS). The treatment also effectively met several secondary endpoints. In a statement, Minerva’s CEO Dr. Remy Luthringer said that the results depict the meaningful benefit of the drug and support its further development. Dr. Luthringer said that the company’s drug has the potential to address the currently unmet medical needs in the treatment of mood disorders and other central nervous system problems, which are not addressed by existing therapies.

How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of capital and have to conduct due diligence while choosing their next pick. They don’t always get it right, but, on average, their stock picks historically generated strong returns after adjusting for known risk factors (see the details here). With this in mind, let’s take a look at the recent hedge fund activity surrounding Minerva Neurosciences Inc (NASDAQ:NERV).

Heading into the second quarter of 2016, a total of 7 of the hedge funds tracked by Insider Monkey held long positions in this stock, a 75% jump from the end of the fourth quarter of 2015. Those hedge funds held $21.85 million worth of the company’s shares, amounting to 12.90% of its common stock. The massive gains also come a couple of months after one of the company’s Directors made a substantial purchase of shares.

James Dondero’s Highland Capital Management reported owning 889,070 shares of Minerva Neurosciences Inc. (NASDAQ:NERV) in its quarterly 13F for the March quarter. Bihua Chen’s Cormorant Asset Management owned the largest position in Minerva on March 31 among the funds in our database, totaling 1.75 million shares. Israel Englander’s Millennium Management made a $0.1 million investment in the stock during the first quarter. Simon Sadler’s Segantii Capital also opened a new position in the stock during the quarter.

Disclosure: None

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!